C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib

International Journal of Urology

Volumn 19, Issue 10, 2012, Pages 908-913

  Fujita, Tetsuo ^a   Iwamura, Masatsugu ^a   Ishii, Daisuke ^a   Tabata, Ken ichi ^a   Matsumoto, Kazumasa ^a   Yoshida, Kazunari ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Renal cell carcinoma; Sunitinib

Indexed keywords

C REACTIVE PROTEIN; SUNITINIB; THYROTROPIN;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; FATIGUE; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; LIVER METASTASIS; LOCAL METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; PANCREAS METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN MANIFESTATION; SKIN METASTASIS; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LEUKOPENIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PYRROLES; RETROSPECTIVE STUDIES; TASTE DISORDERS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866753214     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03071.x     Document Type: Article

References (24)

1. Motzer RJ, Michaelson MD, Redman BG etal. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24: 16-24.
2. Motzer RJ, Rini BI, Bukowski RM etal. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24.
3. Motzer RJ, Hutson TE, Tomczak P etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 3584-90.
4. Uemura H, Shinohara N, Yuasa T etal. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn. J. Clin. Oncol. 2010; 40: 194-202.
5. Tomita Y, Shinohara N, Yuasa T etal. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 2010; 40: 1166-72.
6. Blay JY, Negrier S, Combaret V etal. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 3317-22.
7. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer 2003; 88: 348-53.
8. Casamassima A, Picciariello M, Quaranta M etal. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 2005; 173: 52-5.
9. Vogl UM, Zehetgruber H, Dominkus M etal. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br. J. Cancer 2006; 95: 691-8.
10. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 2006; 13: 1365-70.
11. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007; 99: 77-80.
12. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-12.
13. Karakiewicz PI, Hutterer GC, Trinh QD etal. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007; 110: 1241-7.
14. Saito K, Tatokoro M, Fujii Y etal. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur. Urol. 2009; 55: 1145-54.
15. Naito S, Yamamoto N, Takayama T etal. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 2010; 57: 317-26.
16. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
17. Heng DY, Xie W, Regan MM etal. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009; 27: 5794-9.
18. Han KS, Jung DC, Choi HJ etal. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 2010; 116: 2332-42.
19. Yuasa T, Urakami S, Yamamoto S etal. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. Urology 2011; 77: 831-5.
20. Rini BI, Cohen DP, Lu DR etal. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 2011; 103: 763-73.
21. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr. Cancer 1998; 31: 101-5.
22. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 2002; 87: 264-7.
23. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br. J. Cancer 2004; 91: 1236-8.
24. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br. J. Cancer 2004; 90: 1704-6.